Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 3 | Radiation Oncology

Figure 3

From: The comparison between weekly and three-weekly cisplatin delivered concurrently with radiotherapy for patients with postoperative high-risk squamous cell carcinoma of the oral cavity

Figure 3

Preliminary results. After a median follow-up period of 12.0 months, the overall survival (OS) and locoregional recurrence-free survival (LRRFS) were not different between the two groups. (a) The 1-year OS was 79.3% and 71.6% for patients in arm A and arm B, respectively (p = 0.978). (b) The 1-year LRRFS was 71.1% and 60.0% for patients in arm A and arm B, respectively (p = 0.806).

Back to article page